Psychedelics

Missouri House Passes Public Safety Omnibus HB3068

In April 2026 the Missouri House passed omnibus public-safety bill HB3068 tightening fentanyl and carfentanil trafficking thresholds, broadening drug-induced-death liability, piloting tightly controlled psilocybin use for veterans and first responders, and increasing penalties for damaging critical infrastructure facilities. If enacted in its current form by August 2026, the bill would materially raise criminal and operational risk around potent opioids and critical energy and chemical assets in Missouri while opening a narrow, regulated pathway for psychedelic-assisted therapy research.

23 Apr 2026, 08:27documents.house.mo.govUnited States

Missouri Senate Bill 1682 Proposes Psilocybin Therapy Safe Harbour for Veterans and First Responders

Missouri lawmakers are considering Senate Bill 1682, which would establish a tightly controlled safe harbour for psilocybin-assisted therapy for certain veterans and first responders and broaden the state right-to-try framework to cover Schedule I substances. If enacted, this bill would open a regulated pathway for psilocybin treatment and research in Missouri, signalling a material shift in state controlled-substances policy that mental health providers, hospitals, and emerging psychedelic-therapy businesses would need to track closely.

22 Apr 2026, 19:48senate.mo.govUnited States

Czech Food Inspectorate Flags Muscimol-Containing Psillys Psychedelic Gummies as Dangerous Food

On 13 April 2026, Czech food inspectors classified "Psillys Legal Psychedelic Mushrooms Infused Gummies – Fruit Punch" as a dangerous food after detecting the psychoactive substance muscimol in an official control sample. The case signals that confectionery marketed as "legal psychedelics" in Czechia will face strict enforcement if it contains psychoactive ingredients, elevating compliance and product-liability risks for online sellers and importers.

21 Apr 2026, 13:56potravinynapranyri.czCzechia

South Korea Amends Chemicals Control Act To Ban Promotional Content On Psychedelic Substances

South Korea has adopted a partial amendment to the Chemicals Control Act that, from 7 October 2026, bans labels, advertising and online content which promote intoxicating use of specified “psychedelic” solvents and gases such as toluene, methanol, butane and nitrous oxide. Chemical manufacturers, distributors, brand owners and online platforms serving the Korean market now need to review packaging, marketing and user-facing content for these substances to remove any content that could be interpreted as encouraging inhalant abuse, or face new criminal penalties.

19 Apr 2026, 14:45law.go.krSouth Korea

Iowa Amendment S-5119 Refines HF 978 Medical Psilocybin Licensing and Governance

Iowa’s Health and Human Services Committee has filed amendment S-5119 to HF 978, refining a proposed medical psilocybin regime by reshaping governance, limiting eligibility to adults with PTSD, and shifting key programme milestones into 2027–2029. If enacted, this would create a tightly controlled, state-licensed psilocybin supply chain in Iowa, signalling future compliance obligations and market opportunities for specialised growers, labs, and therapy providers but with no immediate duties until the bill advances.

16 Apr 2026, 10:03legis.iowa.govUnited States

West Virginia Enacts SB 906 To Permit FDA‑Approved Psilocybin Once Federally Rescheduled

West Virginia has enacted SB 906, effective 12 June 2026, amending its controlled substances law so that FDA‑approved, DEA‑rescheduled psilocybin medicines can be lawfully prescribed, distributed, and marketed in the state. This creates a conditional pathway for future medical psilocybin products but leaves psilocybin in Schedule I until specific federal approvals and rescheduling occur, signalling a controlled but significant potential new market for compliant manufacturers and distributors.

15 Apr 2026, 19:30wvlegislature.govUnited States

US DEA Seeks Comment on MDMA Importer Registration for Fisher Clinical Services, Inc.

The US DEA is processing an application to import MDMA for clinical research, with public comments and hearing requests due by May 1, 2026. This highlights the rigorous federal oversight of psychedelic supply chains, where access remains strictly limited to controlled medical trials rather than commercial distribution.

4 Apr 2026, 10:55federalregister.govUnited States

Iowa Legislative Subcommittee Schedules 1 April 2026 Hearing on HF 978 (Psilocybin Bill)

Iowa is advancing legislation to establish a regulated medical psilocybin framework with licensing for production and therapy potentially starting in July 2026. This development signals a shift toward a state-controlled psychedelics market requiring rigorous compliance with production, testing, and inventory standards.

3 Apr 2026, 18:33legis.iowa.govUnited States

US DEA Invites Comments on Importer Registration Application for Research Triangle Institute

The US DEA is reviewing an application to import Schedule I and II controlled substances for research purposes with a comment deadline of May 1, 2026. This administrative process underscores federal control over restricted substance movement and allows domestic manufacturers to monitor and potentially challenge new import registrations.

2 Apr 2026, 17:06federalregister.govUnited States

US DEA Invites Comment on SpecGx LLC Bulk Manufacturer Registration for Schedule I and II Controlled Substances

The US DEA has opened a comment period on an application by SpecGx LLC to register as a bulk manufacturer for a wide range of Schedule I and II controlled substances. This move signals potential shifts in domestic supply chains and quota allocations for highly regulated substances, impacting competitive positioning and market access for existing manufacturers.

27 Mar 2026, 18:17govinfo.govUnited States

South Carolina House Bill 5397 Proposes Schedule I Controls for Substituted Tryptamines

South Carolina introduced legislation in March 2026 to classify a broad range of substituted tryptamines as Schedule I controlled substances. The proposal expands state-level restrictions to include numerous psychedelic analogues, signaling a tightening regulatory environment for synthetic compounds and research chemicals.

27 Mar 2026, 07:52scstatehouse.govUnited States

New Mexico DOH Proposes Rule 7.35.2 NMAC on Medical Psilocybin Producers and Laboratories

New Mexico is establishing a formal regulatory framework for medical psilocybin production and laboratory testing with a public hearing set for April 2026. Prospective operators must prepare for stringent compliance requirements covering traceability, mandatory contaminant testing, and sanitation standards aligned with federal food safety codes.

27 Mar 2026, 06:59nmhealth.orgUnited States

Georgia SB 631 Would Fund FDA-Approved Ibogaine Clinical Trials for Veterans

Georgia introduced legislation to establish state-funded grants for FDA-approved clinical trials using ibogaine for veteran mental health treatments. This initiative reflects a growing state-level shift toward supporting psychedelic research, potentially accelerating the path to market for novel therapeutic substances.

26 Mar 2026, 19:18legis.ga.govUnited States

Minnesota HF4577 Would Establish Psilocybin Therapeutic Use Program and Reschedule Psilocybin

Minnesota has introduced legislation to establish a state-regulated therapeutic psilocybin program and reschedule the substance to Schedule IV by 2027. This proposal creates a structured pathway for medical psychedelic access, requiring stakeholders to navigate rigorous state-level cultivation, testing, and clinical administration standards.

26 Mar 2026, 19:06revisor.mn.govUnited States

South Carolina Bill S1039 Would Add Substituted Tryptamines to Schedule I Controlled Substances

South Carolina introduced legislation in March 2026 to expand its Schedule I controlled substances list by adding a broad category of substituted tryptamines. If enacted, this would criminalize the possession and distribution of numerous psychedelic analogues, requiring immediate portfolio reviews for research, pharmaceutical, or chemical supply operations in the state.

22 Mar 2026, 17:03scstatehouse.govUnited States

US DEA Announces Siegfried Grafton Application To Import Schedule I Controlled Substances

The US DEA is processing a formal request to import Schedule I controlled substances for analytical testing and distribution purposes. This highlights the ongoing demand for restricted pharmaceutical precursors in research and development and reinforces the strict regulatory controls governing the secure international supply chain.

20 Mar 2026, 13:48federalregister.govUnited States

Iowa Senate Subcommittee Schedules Hearing On HF 978 Medical Psilocybin Framework

Iowa is advancing legislation to establish a regulated medical psilocybin market, with licensing for production and testing facilities proposed to begin in July 2026. Prospective operators must prepare for rigorous cultivation standards, mandatory potency testing, and strict labeling requirements to mitigate compliance and recall risks.

19 Mar 2026, 19:21legis.iowa.govUnited States

Minnesota House Committee Advances Psilocybin Therapeutic Use Bill Reclassifying Psilocybin/Psilocin (H.F. 2906)

Minnesota is advancing legislation to create a regulated psilocybin therapeutic framework and reclassify psilocybin and psilocin as Schedule IV substances. This transition signals a shift toward medicalized psychedelic markets, requiring businesses to prepare for stringent licensing, product testing, and clinical oversight standards.

18 Mar 2026, 16:25house.mn.govUnited States

US DEA Seeks Comments on Psilocybin Importer Registration Application by Lonza Tampa LLC

The US Drug Enforcement Administration is reviewing an application to import psilocybin for clinical research and analytical use, with public comments due by mid-April 2026. This development signals a continuing, albeit highly regulated, opening for psychedelic-based pharmaceutical development while reinforcing strict prohibitions on commercial-scale imports of finished products.

13 Mar 2026, 06:28public-inspection.federalregister.govUnited States

California Assembly Introduces AB 2489 Veterans’ Right To Try Act For Psychedelic Research

California introduced legislation in early 2026 to establish an expedited state-level approval pathway for clinical research involving psilocybin and ibogaine. This move signals a shift toward state-led oversight of controlled substance trials, offering pharmaceutical developers a potential route to accelerate development timelines for psychedelic therapies.

12 Mar 2026, 09:16leginfo.legislature.ca.govUnited States